Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes

Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves β-cell function for at least 12 months in type 1 diabetes. Herein, we describe metabolic and immunological parameters 24 months following treatment. Patients with established type 1 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Haller, Michael J., Gitelman, Stephen E., Gottlieb, Peter A., Michels, Aaron W., Perry, Daniel J., Schultz, Andrew R., Hulme, Maigan A., Shuster, Jonathan J., Zou, Baiming, Wasserfall, Clive H., Posgai, Amanda L., Mathews, Clayton E., Brusko, Todd M., Atkinson, Mark A., Schatz, Desmond A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2016
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127248/
https://www.ncbi.nlm.nih.gov/pubmed/27669730
http://dx.doi.org/10.2337/db16-0823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127248/
https://www.ncbi.nlm.nih.gov/pubmed/27669730
http://dx.doi.org/10.2337/db16-0823

Ejemplares similares